Real-world use of bevacizumab-awwb, a bevacizumab biosimilar, in US patients with metastatic colorectal cancer

Abstract

<b>Aim:</b> Evaluated real world use of bevacizumab-awwb (MVASI^®), a bevacizumab biosimilar, for treating metastatic colorectal cancer (mCRC). <b>Materials & methods:</b> Adult mCRC patients who received bevacizumab-awwb during the first year after market availability were identified from the ConcertAI oncology dataset. <b>Results:</b> Of 304 patients, 47% initiated bevacizumab-awwb as reference product (RP) naive patients and 53% received bevacizumab-awwb with prior exposure to RP. Overall, 78% received bevacizumab-awwb as first-line therapy; the proportion was higher (91%) in RP-naive patients. Among RP-experienced patients, 83% were transitioned from RP to bevacizumab-awwb in the same line without disease progression; of those, the majority (83%) were transitioned within 28 days. <b>Conclusion:</b> Early evidence from US oncology practices suggests clinical adoption of bevacizumab-awwb in treating mCRC patients.